Development of Seraseq FFPE Homologous Recombination Deficiency Reference Materials for NGS Assay Validation

Download this Scientific Poster

Homologous recombination deficiency (HRD) arises due to a defect in DNA repair and serves as an important therapeutic biomarker. NGS assays that measure HRD status via genomic instability are used to stratify ovarian and breast cancer patients and determine eligibility for clinical trials, and PARP inhibitor and platinum based therapies. 

To learn how the newly launched Seraseq HRD reference materials support the development, validation, and routine determination of HRD status in cancer patients, download this scientific poster by filling out the form.